[Pharmacokinetic studies on cefmenoxime. Distribution into the uterus and intrapelvic genital organs].
Concentrations of cefmenoxime (CMX) in peripheral venous serum, uterus and intrapelvic genital organs were determined by bioassay. The obtained results are summarized below. When 1 g of CMX was administered by an intravenous injection, peak concentrations in various tissues of female genital organs were as follow: 17.4 and 46.8 micrograms/g in ovary and oviduct, respectively, and from 28.2 to 43.8 micrograms/g in other genital organs. These concentrations of CMX were maintained at higher level than minimal inhibitory concentrations against E. coli, Bacteroides and other organisms. In these studies, CMX showed a satisfactory clinical efficacy and a potent antibacteriological effect in the treatment of infections in the field of obstetrics and gynecology.
Shindo
K
K
Tsuburaya
T
T
Atsumi
Y
Y
Sato
M
M
D000328:Adult; D015281:Cefmenoxime; D002439:Cefotaxime / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism; D005187:Fallopian Tubes / Q000378:metabolism*; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D007275:Injections, Intravenous; D007700:Kinetics; D008875:Middle Aged; D010053:Ovary / Q000378:metabolism*; D014599:Uterus / Q000378:metabolism*
D015281:Cefmenoxime; D002439:Cefotaxime